维多利亚老品牌76696vic-在线入口

Be the most trusted biotech company

2024-05-22

The Supplemental Applications of HANDAYUAN(adalimumab injection) for the New Indications Approved by the NMPA
2024-05-21

Henlius to Release Latest Clinical Data of HLX22 at 2024 ESMO GI
2024-05-16

Henlius to Showcase at BIO 2024
2024-05-15

First Patient Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2024-05-14

Henlius lasofoxifene HLX78 IND Approved by NMPA
2024-05-10

Henlius Holds its first Scientific Advisory Board Meeting of 2024
2024-05-06

Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA
2024-04-29

Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products
2024-04-26

Henlius Trastuzumab Receives FDA Approval in the United States

1
2
3
4
5
6
7
8